Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 8896 results

  1. Newer drugs for epilepsy in adults (TA76)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  2. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042

    Withdrawn guidance

  3. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Withdrawn guidance

  4. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Withdrawn guidance

  5. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1045.

    Withdrawn guidance

  6. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1054.

    Withdrawn guidance

  7. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

    Withdrawn guidance

  8. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Withdrawn guidance

  9. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Withdrawn guidance

  10. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  11. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    This guidance has been updated and replaced by NICE technology appraisal guidance 824.

    Withdrawn guidance

  12. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  13. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  14. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Withdrawn guidance

  15. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Withdrawn guidance